Cancer control by adaptive immunity involves a number of defined death [1] [2] [3] [4] [5] [6] [7] [8] and clearance [9] [10] [11] mechanisms. However, efficient inhibition of exponential cancer growth by T cells and interferon-c (IFNc) requires additional undefined mechanisms that arrest cancer cell proliferation [1] [2] [3] [4] [5] 12, 13 . Here we show that the combined action of the T-helper-1-cell cytokines IFN-c and tumour necrosis factor (TNF) directly induces permanent growth arrest in cancers. To safely separate senescence induced by tumour immunity from oncogene-induced senescence [9] [10] [11] [14] [15] [16] [17] , we used a mouse model in which the Simian virus 40 large T antigen (Tag) expressed under the control of the rat insulin promoter creates tumours by attenuating p53-and Rb-mediated cell cycle control 18, 19 . When combined, IFN-c and TNF drive Tag-expressing cancers into senescence by inducing permanent growth arrest in G1/G0, activation of p16INK4a (also known as CDKN2A), and downstream Rb hypophosphorylation at serine 795. This cytokine-induced senescence strictly requires STAT1 and TNFR1 (also known as TNFRSF1A) signalling in addition to p16INK4a. In vivo, Tag-specific T-helper 1 cells permanently arrest Tag-expressing cancers by inducing IFN-c-and TNFR1-dependent senescence. Conversely, Tnfr1
2/2
Tag-expressing cancers resist cytokine-induced senescence and grow aggressively, even in TNFR1-expressing hosts. Finally, as IFN-c and TNF induce senescence in numerous murine and human cancers, this may be a general mechanism for arresting cancer progression.
Recent studies from targeted cancer immunotherapies show that adaptive immunity can efficiently control human cancer [20] [21] [22] [23] [24] . Many cancer immunotherapies do not cause cytotoxic cancer cell elimination, but instead arrest cancer growth or induce slow cancer regression 21, 22 , despite the fact that immunotherapeutic strategies generally focus on CD8 1 cytotoxic T lymphocytes (CTL) or natural killer cells [1] [2] [3] [4] [5] [6] [7] [8] 23, 24 . Moreover, where studied, growth arrest and cancer regression correlate with tumour-specific, IFN-c-producing CD4 1 T-helper 1 (T H 1) cells rather than CTLs [20] [21] [22] [23] . In addition, profiling of patients in clinical cancer trials shows a critical role for IFN-c and TNF in cancer control 25, 26 . Similarly, efficient immune control of murine cancers resulting from aberrant cell cycle control, oncogene expression and chemical or viral transformation strictly requires IFN-c [3] [4] [5] [6] [7] 12, 27 . In consequence, IFN-cand TNF-producing T H 1 cells specific for the tumour antigen Tag (Tag-T H 1 cells) restrain Tag-induced islet cancers in mice expressing Tag under the control of the rat insulin promoter (RIP-Tag2 mice; in which Tag2 indicates a mouse strain that carries five copies of the transgene) in all pancreatic islet cells 12, 18 . T H 1 immunity doubles the lifespan of mice through strictly IFN-c-and TNFR1-dependent mechanisms 12 , without causing detectable signs of cytotoxicity, tumour cell necrosis or apoptosis 12 . This was surprising, as Tag expression causes invasive b-cell cancers (b-cancers) in 2% of the islets by incomplete Rb suppression and p53 silencing 18, 19 .
Only CD4
1 T H 1 cells that produce IFN-c and TNF and are specific for Tag peptide induce IFN-c-and TNFR1-dependent arrest of RIPTag2 tumours ( Supplementary Fig. 1a-c) 
12
. This arrest occurs also in the absence of notable T-cell infiltration (Supplementary Figs 1c and 2)   12 and is independent of both CTLs 12 and enhanced apoptosis, as determined by TdT-mediated dUTP nick end labelling (TUNEL) assay 12 and caspase 3 staining, respectively. Moreover, IFN-c-exposed b-cancer cells failed to express major histocompatibility complex (MHC) class II in vivo as well as in vitro, a prerequisite for cancer killing by T H 1 cells. In consequence, Tag-T H 1 cells failed to kill IFN-c-stimulated b-cancer cells in vitro ( Supplementary Fig. 3 ). In addition, as Tag-T H 1 cells enhance, rather than attenuate, the growth of Tnfr1 2/2 b-cancers
( Supplementary Fig. 1 ), TNFR1-independent killing-for example, by perforin-granzyme B-mediated lysis-could not account for substantial control of b-cancers by Tag-T H 1 cells. Instead, Tag-T H 1 cells form follicle-like structures around the islets, where they interact with antigen-presenting cells 12 . Ki67 staining confirmed that Tag-T H 1 cells arrested proliferation of b-cancers in vivo ( Supplementary Fig. 4a ). Freshly isolated b-cancer cells from Tag-T H 1-cell-treated RIP-Tag2 mice failed to proliferate in vitro, whereas b-cancer cells from shamtreated mice strongly incorporated 3 H-thymidine ( Supplementary  Fig. 4b ). This suggests that T H 1 cytokines induce growth arrest in vivo, despite normal Tag expression ( Supplementary Fig. 5 ).
To assess directly whether IFN-c and TNF induce senescence in b-cancers, we cultured freshly isolated b-cancer cells from shamtreated mice treated with either control medium, or with IFN-c and TNF. In cell cycle analysis, untreated b-cancer cells were $25% in S phase and 40% in G1/G0, explaining their rapid proliferation. When combined, IFN-c and TNF arrested most b-cancer cells in G1/G0 within 3 days (Fig. 1a) . They reduced S-phase cells to 3% and increased the G1/S ratio 20-fold (Fig. 1b) without increasing the apoptotic sub-G1 fraction (Fig. 1a) . As IFN-c and TNF arrested the b-cancer cells in G1/G0, a state characterizing cellular senescence, we wanted to know whether IFN-c and TNF caused senescence-defining permanent growth arrest.
Freshly isolated b-cancer cells proliferated rapidly in medium. When cultured in the presence of IFN-c and TNF, b-cancer cells were fully growth arrested (Fig. 1c) . To determine whether the growtharrested b-cancer cells were really senescent, we washed the cells on day 5 and cultured them for another 2 weeks with medium only. Although untreated b-cancer cells continued to expand, b-cancer cells that had been exposed for 5 days to the combined action of IFN-c and TNF were truly senescent, as they remained fully growth arrested (Fig. 1c) . Even 2 weeks after withdrawal of IFN-c and TNF, the b-cancer cells failed to incorporate 5-bromo-2-deoxyuridine (BrdU), whereas untreated controls strongly incorporated BrdU (Fig. 1d, e and Supplementary Fig. 6 ).
IFN-c and TNF also induced characteristic senescence-associated epigenetic and lysosomal changes, such as nuclear recruitment of phosphorylated heterochromatin protein 1c (pHP1c) into senescence-associated heterochromatin foci or senescence-associated b-galactosidase (SA-b-gal) activity. Time-course studies revealed that within 3 days, IFN-c and TNF induced the early senescence marker pHP1c in 75% ( Supplementary Fig. 7a, b) and SA-b-gal in 50% of the b-cancer cells (Fig. 2a, b) . However, induction of stable growth arrest and the late senescence marker SA-b-gal in 80% of the cells needed $4 days of incubation with both IFN-c and TNF (Fig. 2c) . Double-staining with synaptophysin, an islet cell marker, confirmed SA-b-gal expression by b-cancer cells (Supplementary Fig. 8 ). Combined IFN-c and TNF treatment established the senescencedefining permanent growth arrest in b-cancers cells, whereas neither IFN-c nor TNF alone was sufficient to induce full growth arrest ( Supplementary Fig. 6 ), although early signs of senescence, such as pHP1c recruitment to senescence-associated heterochromatin foci ( Supplementary Fig. 7a, b) and SA-b-gal positivity in 40% of the cells, were observed (Fig. 2c) .
As combined stimulation of islets or islet tumours with IFN-c and TNF strongly induces JUNB 28 , the combined IFN-c STAT1 and TNFR1 signalling may activate the JUNB downstream target p16INK4a and thus stabilize the p16INK4a-Rb senescence pathway in Tag-expressing b-cancers. Indeed, IFN-c and TNF strongly induced p16INK4a in subconfluent cultures within 48 h (Fig. 2d) , whereas p16INK4a remained weak in medium-treated subconfluent b-cancer cells (Fig. 2d) . This induction of p16INK4a also caused sustained and severe hypophosphorylation of Rb at Ser 795 (Fig. 2e) . Corresponding to the conjoint IFN-c-and TNF-induced senescence through stabilization of the p16INK4a-Rb pathway in b-cancer cells, short hairpin RNA (shRNA)-mediated knockdown of p16INK4a and p19 (hereafter termed p16-p19, in which p19 refers to an alternate reading frame of 
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the Ink4a/Arf (Cdkn2a) locus) fully abrogated senescence induction by IFN-c and TNF ( Fig. 2f and Supplementary Fig. 9 ). In line with this, STAT1-or TNFR1-deficient b-cancer cells fully resisted senescence induction by IFN-c and TNF, showing that hypophosphorylation of Rb strictly requires the combined action of the STAT1 and TNFR1 signalling pathways (Fig. 2b, g ).
IFN-c and TNF induced senescence in breast cancers from polyomavirus middle T antigen (PyVmT)-transgenic mice (Supplementary Fig. 10 ), in 3 out of 6 mouse tumour lines (Supplementary Table 1 ), in human A204 rhabdomyosarcoma cells ( Supplementary Fig. 11 ), in 6 out of 11 IFN-receptor-and TNF-receptor-expressing human cancers from the National Cancer Institute's NCI-60 panel (Supplementary  Table 2 ), and in freshly isolated primary melanoma or sarcoma cells (Supplementary Table 3 ). Interestingly, primary melanomas frequently show areas of inflammation and regression. Such tumour areas harboured senescent melanoma cells strongly expressing p16INK4a but not the proliferation marker Ki67, whereas p16INK4a-deficient melanoma cells strongly expressed Ki67 even in the presence of an inflammatory infiltrate (Supplementary Fig. 12 ). Thus, cytokineinduced senescence was not restricted to Tag-expressing b-cancers, but seems to be of broad relevance for tumour immunotherapy and may cause tumour dormancy in sporadic human melanomas.
Combined IFN-c and TNFR1 signalling is also necessary to arrest b-cancers in vivo 12 ( Supplementary Fig. 1 ) and a senescence-like phenotype was observed in spontaneously regressing melanomas. Thus, the in vitro and in vivo data suggest that T H 1 immunity arrested cancer progression through IFN-c-and TNF-induced senescence in vivo. To test this hypothesis, we first quantified senescenceassociated chromatin changes by counting cancer cells positive for pHP1c, trimethylation of histone 3 lysine 9 (H3K9me3), or apoptosisassociated active caspase 3 by immunohistology in either sham-treated mice or mice treated with Tag-T H 1 cells. T H 1 immunity significantly increased pHP1c-and H3K9me3-positive nuclei in b-cancers, but not caspase-3-positive cells (Fig. 3a, b ).
To address whether T H 1 immunity also activated the p16INK4a-Rb pathway in vivo, we double-stained sections for p16INK4a and the proliferation marker Ki67. In sham-treated mice, the b-cancer cells were $30% Ki67 positive and only 5% p16INK4a positive. T H 1 immunity diminished Ki67 1 cells to 3%, and increased the fraction of p16INK4a 1 cells (nuclear and cytoplasmic) to $20% (Fig. 3c, d and Supplementary Fig. 13 ).
Senescence induction by T H 1 immunity in vivo also strictly required TNFR1 signalling. Tnfr1 2/2 b-cancers failed to increase pHP1c, H3K9me3 or active caspase 3 when treated with Tag-T H 1 cells ( Supplementary Fig. 14a, b) . In addition, whether isolated from shamor Tag-T H 1-treated mice, Tnfr1 2/2 b-cancer cells expressed Ki67 but not p16INK4a (Fig. 3c, d) , even though Tag-T H 1 cells migrate into pancreata of Tnfr1 2/2 RIP-Tag2 mice 12 .
As T H 1 immunity severely impaired b-cancer growth in vivo 12 , these data strongly suggest that the combined IFN-c and TNFR1 signalling also drove cancers into senescence in vivo.
The most stringent criterion defining senescence is stable and permanent growth arrest in the absence of T H 1 immunity 9, 15, 16 . We therefore cultured freshly isolated b-cancer cells from 12-week-old mice with medium only. Cells from sham-treated RIP-Tag2 mice first suffered a critical loss and then re-initiated proliferation, yielding 10-20 3 10 5 b-cancer cells per pancreas after three passages (Fig. 4a) . By contrast, b-cancer cells from RIP-Tag2 mice treated with Tag-T H 1 cells were truly senescent, as they failed to proliferate over three passages and stably yielded only 0.5-2.0 3 10 5 cells per pancreas (Fig. 4a) . The T H 1-induced growth arrest remained stable when cultures were extended for six passages (Supplementary Fig. 15 ). At 12 weeks, b-cancers from Tnfr1 2/2 RIP-Tag2 mice yielded similar cell counts as those from RIP-Tag2 mice (Fig. 4a) . In vitro, Tnfr1
b-cancer cells grew exponentially, yielding 100 3 10 5 cells within three passages even when derived from Tag-T H 1-treated mice (Fig. 4a) .
To determine whether senescence was also maintained in vivo, we re-implanted the four different b-cancer cell lines after the third passage under the skin of non-obese diabetic-severe combined immunodeficient (NOD-SCID) Il2rg 2/2 mice, as growth at ectopic sites characterizes cancers 2 . Within 7 weeks, as few as 1.2 3 10 5 b-cancer cells from sham-treated RIP-Tag2 mice significantly decreased blood glucose (Fig. 4b) and increased the serum insulin levels (Fig. 4c) , demonstrating the metastatic potential of b-cancer cells from shamtreated mice. Senescent b-cancers from RIP-Tag2 mice treated with Tag-T H 1 cells also remained growth arrested in vivo, as blood glucose remained stable in all transplanted mice throughout the 7 weeks (Fig. 4b) . Minute adenomas in some NOD-SCID Il2rg 2/2 mice and marginally increased serum insulin (Fig. 4c) showed that the transplanted cells survived but remained growth arrested for $10 weeks of in vitro and in vivo culture. Again, senescence-resistant Tnfr1 2/2 RIPTag2 b-cancer cells grew rapidly after transplantation and as little as 1.2 3 10 5 Tnfr1 2/2 RIP-Tag2 cancer cells rapidly decreased blood glucose (Fig. 4b) , irrespective of whether they were derived from shamtreated or Tag-T H 1-treated mice. Transplanting 60% of total b-cancer cells from sham-treated RIP-Tag2 mice generated tumours within 7 weeks, whereas b-cancer cells from Tag-T H 1-cell-treated mice failed to grow (Fig. 4d) . Only 10% of b-cancer cells from sham-or Tag-T H 1-treated Tnfr1 2/2 RIP-Tag2 mice generated large tumours within the same timeframe (Fig. 4d) . 
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Oncogenes, DNA damage and chemotherapeutics induce senescence that, in human cells, is reinforced by the senescence-associated secretome [14] [15] [16] [17] 29, 30 . Uncovering that adaptive T H 1 immunity directly restrains cancer proliferation through IFN-c-and TNF-induced cancer cell senescence provides a long-searched-for direct mechanism explaining the anti-proliferative effects of T H 1 immunity on cancers 2, 3 . T H 1 immunity can induce antiangiogenic chemokines 12 , even in cancer cells ( Supplementary Fig. 16a, b) , and permanent growth arrest leading to cancer cell senescence. Although both effects protect against cancer 12, 18 , p16-p19 knockdown experiments revealed that the arrest of cancer growth strictly needed T H 1-induced senescence. shRNAmediated knockdown of p16-p19 affected neither the IFN-c-and TNF-induced mRNA expression nor protein production of antiangiogenic chemokines, but it fully abrogated senescence. Following the p16-p19 knockdown, b-cancer cells grew exponentially in the presence of IFN-c, TNF and the antiangiogenic chemokines CXCL9 and CXCL10 (Fig. 2f and Supplementary Fig. 16c, d) . Importantly, this is also valid in vivo. Despite the absence of antiangiogenic signals, senescent cancers remained growth arrested when transferred into NOD-SCID Il2rg 2/2 mice (Fig. 4b, c) . As the T H 1-induced cancer cell senescence thus explains the therapeutic efficiency of tumour-specific T H 1 immunity in early cervical cancer 21 and disseminated melanoma 20 , T H 1-cytokine-induced senescence may be of broad relevance for cancer control, also in humans under therapeutic conditions.
METHODS SUMMARY

RIP-Tag2 and Tnfr1
2/2 RIP-Tag2 mice were either sham-treated or treated with Tag2-specific T H 1 cells starting at week 6. Cancer cells were isolated by consecutive collagenase-trypsin digestion from tumour tissues of RIP-Tag2, Stat1 2/2 RIPTag2, Tnfr1 mice, and tumour growth was monitored with a caliper and by measuring blood glucose and insulin levels.
Full Methods and any associated references are available in the online version of the paper. , Serva) for 10 min at 37 uC, and then separated under a dissection microscope (Leica Microsystems). Tumour cells were obtained by incubation in 0.05% trypsin/EDTA solution (Invitrogen) at 37 uC for 10 min, and seeded on tissue culture plates. Adherent cells were cultured for 2-7 weeks in RPMI 1640 supplemented with 10% fetal calf serum, non-essential amino acids, antibiotics and 50 mM 2-mercaptoethanol at 37 uC and 5% CO 2 . The murine cancer cell lines B16, LLC and CT26 EpCam 36 in addition to 11 human cancer cell lines from the NCI-60 panel 37 , six primary human cancer cell preparations and human rhabdomyosarcoma cells (A204 cells) were grown in complete RPMI 1640 medium. If not otherwise stated, subconfluent cells were treated with 100 ng ml 21 mouse or human IFN-c (R&D Systems), or 10 ng ml 21 mouse or human TNF (R&D Systems), or with a combination of mouse or human IFN-c (50-100 ng ml
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20. Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD41 T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008). 21. Kenter
21
) and mouse or human TNF (0.1-10 ng ml
) for 2-6 days. bcancer cells were identified by immunofluorescence using an anti-synaptophysin antibody (undiluted; Lifespan Biosciences). Knockdown of p16INK4a. 5 3 10 4 b-cancer cells were seeded in 6-well culture plates. After 72 h, cells were transfected with 2 ml cell culture supernatant containing shCtrl or shp16-p19 MSCV vectors 38, 39 in the presence of 1 mg ml 21 polybrene (Sigma) for a total transduction time of 12 h. After 5 days, transduced cells were selected by treatment with 1 mg ml 21 puromycin (Sigma) for 72 h. The transduction rate was determined by counting green fluorescent protein-positive cells under a Zeiss Axiovert 200 microscope (Zeiss). In vitro proliferation assays. After treatment, cancer cell proliferation was measured either by the [ In vitro growth-arrest assays. The different cancer cells were seeded at a density of 1 3 10 4 cells cm
22
. Next, the cells were treated with control medium or cytokines as described above for 4-5 days. After treatment, the cells were trypsinized and viable cells (trypan blue exclusion) were counted under a Zeiss Axiovert 25 microscope (Zeiss) using a Neubauer counting-chamber (Karl Hecht GmbH). The cells were seeded at 2 3 10 4 cells cm 22 and grown in complete RPMI 1640 medium until the control cultures reached confluence. Then, the cells were trypsinized, counted and seeded again. After passage 1-2, 1,000-3,000 viable cells were seeded on Multiscreen TM HTS 96 well Filtration Plates (Millipore), and proliferation was measured by the BrdU-based Cell Proliferation ELISA (Roche Diagnostics) in combination with the VectorSG Substrate Kit for Peroxidase from Vector Laboratories to visualize BrdU-incorporating cell clusters. BrdU-positive spots were counted with an ELISPOT reader (Bioreader-3000; Bio-Sys). In addition, some cultures were stained with 49,6-diamidino-2-phenylindole (DAPI; Invitrogen) to visualize the nuclei of adherent cells. Analysis of CXCL9 or CXCL10 in the supernatant of b-cancer cells. b-cancer cells were either treated with medium alone or with IFN-c and TNF. After 24 h incubation, CXCL9 or CXCL10 levels were determined in the cell culture supernatants using the mouse CXCL9 or mouse CXCL10 ELISA kit from R&D Systems. Treatment of mice with Tag-T H 1 cells. Before the first Tag-T H 1-cell-based therapy, all mice received 2-Gy total-body irradiation. Then, 1 3 10 7 Tag-T H 1 cells in 0.9% NaCl solution (Tag-T H 1) or NaCl solution alone (sham) was injected intraperitoneally once per week starting at week 6 (ref. 12). After 6 weeks of Tag-T H 1 treatment, all mice received a second 2-Gy total-body irradiation 12 . Blood glucose was measured using an Accu-Check sensor (Roche Diagnostics). If not otherwise stated, mice were euthanized at week 12.
Transfer of b-cancer cells into immune-deficient mice. b-cancer cells isolated from the various groups of mice were cultured for three passages. Then, 10-60% of the b-cancer cells were injected subcutaneously into immune-deficient NOD-SCID Il2rg 2/2 mice. Tumour growth was monitored with a caliper, and blood glucose was measured using an Accu-Check sensor for up to 7 weeks. Serum insulin levels were determined using the rat/mouse insulin ELISA kit from Millipore. Immunofluorescence and immunohistochemistry. The different cancer cells were grown on chamber slides (BD Biosciences). After treatment, the cells were fixed with acetone/methanol 1:1. The slides were washed with PBS buffer and 0.05% Tween 20 at room temperature (21-23 uC), blocked with serum-free DAKO-Block (DAKO), washed again, and then incubated with the following antibodies: anti-Ki67 (dilution 1:100; Abcam), anti-PCNA (dilution 1:100; Cell Signaling Technology), anti-pHP1c (dilution 1:100; Abcam), anti-H3K9me3 (dilution 1:500; Millipore,), anti-p16INK4a (dilution 1:100; Santa Cruz Biotechnology), anti-SV40 Tag (dilution 1:100; BD Biosciences), anti-MHCII (dilution 1:50; eBioscience) or anti-synaptophysin (undiluted; Lifespan Biosciences). After washing, the slides were incubated with anti-rabbit Alexa488 (Invitrogen), anti-rabbit-Cy3 (Dianova), anti-mouse Alexa555, or anti-mouse Alexa488 (both from Cell Signaling Technology), washed again and incubated with DAPI (Invitrogen). Finally, the slides were washed, mounted with fluorescence mounting medium (DAKO) and analysed using a Zeiss Axiovert 200 microscope (Zeiss) with the VisiView software (Visitron Systems).
Fresh-frozen cryostat sections of whole pancreata were stained as described 40 . In brief, the sections were fixed with periodate-lysine-paraformaldehyde, blocked with donkey serum (dilution 1:20), and then incubated with rabbit anti-pHP1c (dilution 1:80), mouse anti-PCNA (dilution 1:50), mouse anti-p16INK4a (dilution 1:50), or rabbit anti-Ki67, rat-anti-MHCII (dilution 1:50), or rabbit-antisynaptophysin (undiluted) antibodies. After washing, the sections were incubated with Cy3-conjugated donkey anti-rabbit, donkey anti-mouse, or Cy5-conjugated donkey-anti-rabbit, donkey-anti-mouse, or donkey-anti-rat-dylight 549 and donkey-anti-rabbit-dylight 649 IgG (all from Dianova). Before mounting the slides with Mowiol (Hoechst), nuclei were stained with Yopro (1:2,000; Invitrogen). The sections were analysed using a Leica TCS-Sp/Leica DM RB confocal laser scanning microscope (Leica Microsystems). Images were processed with the Leica Confocal Software LCS (Version 2.61).
Formalin-fixed pancreata were embedded in paraffin. Sections (3-5-mm thick) were cut and stained with haematoxylin and eosin. Immunohistochemistry was performed on an automated immunostainer (Ventana Medical System) according to the manufacturer's protocol, with minor modifications
